Text Size

Idiopathic Pulmonary Fibrosis Registry for Future Studies

This study is currently recruiting participants.
Verified December 2012 by Ohio State University
Sponsor:
Information provided by (Responsible Party):
Clay Marsh MD, The Ohio State University
ClinicalTrials.gov Identifier:
NCT00815711
First received: December 29, 2008
Last updated: December 13, 2012
Last verified: December 2012
History of Changes
  Purpose

To establish a registry of patients for future studies of Inflammation in Interstitial Lung Disease/Idiopathic Pulmonary Fibrosis.


Condition
Lung Disease, Interstitial
Idiopathic Pulmonary Fibrosis

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Inflammation in Interstitial Lung Disease/Idiopathic Pulmonary Fibrosis

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Ohio State University:

Primary Outcome Measures:
  • Framework [ Time Frame: 7 + years ] [ Designated as safety issue: No ]
    To establish a framework in which biologic samples and physiologic measures from patients with IPF can be longitudinally collected and evaluated


Biospecimen Retention:   Samples With DNA

blood serum BAL fluid lung biopsy


Estimated Enrollment: 84
Study Start Date: December 2008
Estimated Study Completion Date: January 2015
Estimated Primary Completion Date: January 2015 (Final data collection date for primary outcome measure)
Detailed Description:

To establish a framework in which biologic samples and physiologic measures from patients with IPF can be longitudinally collected and evaluated. Having a bank of samples that are correlated with physiologic measures that follow patients through their course will allow the following proposed studies as well as future investigations to be efficiently carried out.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

primary care clinic

Criteria

Inclusion Criteria:

  • any patient referred to the Interstitial Lund Disease clinic who is undergoing evaluation and or treatment for a new diagnosis of ILD. This can include patients referred for presumed pulmonary fibrosis/interstitial pneumonitis (IPF, UIP, NSIP), sarcoidosis, hypersensitivity pneumonitis, cryptogenic organising pneumonia, drug-induced, or other idiopathic ILDs.

Exclusion Criteria:

  • pregnancy
  • inability to follow study requirements
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00815711

Contacts
Contact: Janice E Drake, CRTT 614-688-2287 janice.drake@osumc.edu
Contact: Sharon T Cheung, BS 614-366-2258 sharon.cheung@osumc.edu

Locations
United States, Ohio
The Ohio State University Recruiting
Columbus, Ohio, United States, 43210
Contact: Janice E Drake, CRTT            
Sub-Investigator: James N Allen, MD            
Sub-Investigator: Nitin Y Bhatt, MD            
Sub-Investigator: Christopher Baran, PhD            
Sponsors and Collaborators
Clay Marsh MD
Investigators
Principal Investigator: Clay B Marsh, MD Ohio State University
  More Information

No publications provided

Responsible Party: Clay Marsh MD, SR Assoc VP for Health Sciences Research, Vice Dean of Research for the College of Medicine, Executive Director of the Center for Personalized Health Care, Director of the Center for Critical and Respiratory Care, The Ohio State University
ClinicalTrials.gov Identifier: NCT00815711     History of Changes
Other Study ID Numbers: 2007H0002
Study First Received: December 29, 2008
Last Updated: December 13, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by Ohio State University:
IPF

Additional relevant MeSH terms:
Fibrosis
Lung Diseases
Pulmonary Fibrosis
Lung Diseases, Interstitial
 Idiopathic Pulmonary Fibrosis
Pathologic Processes
Respiratory Tract Diseases
Idiopathic Interstitial Pneumonias

ClinicalTrials.gov processed this record on June 17, 2013